What is the difference between CJC-1295 (without DAC) and Follistatin 344?

CJC-1295 (without DAC): CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH analog that binds and activates pituitary GHRH receptors to stimulate brief, pulsatile growth hormone release. Follistatin 344: Binds and neutralizes myostatin (GDF-8) and activin; removes the natural brake on muscle growth allowing supraphysiological hypertrophy

Is Follistatin 344 FDA approved?

Follistatin 344 is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is CJC-1295 (without DAC) administered in research settings?

In research settings, CJC-1295 (without DAC) is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

How is Follistatin 344 administered in research settings?

In research settings, Follistatin 344 is typically administered via the intramuscular route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›CJC-1295 (without DAC) vs Follistatin 344

Peptide Comparison

CJC-1295 (without DAC) vs Follistatin 344

Name: CJC-1295 (without DAC) vs Follistatin 344 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

CJC-1295 (without DAC)

CJC 1295

Fat LossResearch Only

Half-life: ~30 minutes

454 providers listed

Full CJC-1295 (without DAC) profile →

Follistatin 344

FST-344

PerformanceNot EvaluatedResearch Only

Half-life: ~24-36 hours

15 providers listed

Full Follistatin 344 profile →

Bottom line

CJC-1295 (without DAC) and Follistatin 344 target different goals — CJC-1295 (without DAC) for GH and IGF-1 elevation, Follistatin 344 for myostatin and activin A neutralization — dual TGF-β inhibition. They're compared here for reference, not as direct substitutes.

Quick Verdict

CJC-1295 (without DAC)

Half-life

~30 minutes

Follistatin 344

Half-life

~24-36 hours

Different Goals

CJC-1295 (without DAC) and Follistatin 344 target different goals — CJC-1295 (without DAC) for GH / IGF Axis, Follistatin 344 for Muscle & Myostatin. They're compared here for reference; there isn't a single “better” choice between them.

Side-by-Side Comparison

CJC-1295 (without DAC)

Follistatin 344

Mechanism Family

GH / IGF Axis

Muscle & Myostatin

Half-life

~30 minutes

~24-36 hours

FDA Status

nomination withdrawn

not evaluated

Admin Routes

subcutaneous

intramuscular

Availability

Research Only

Providers

454 listed

15 listed

Avail. Notes

GHRH analog — the truncated 1-29 form (Mod GRF 1-29), WITHOUT the Drug Affinity Complex (DAC). No FDA approval; not on the FDA 503A bulks list. WADA prohibited (S2) as a growth-hormone-releasing factor. Sold as a research chemical only.

Myostatin inhibitor. No FDA approval. Gene therapy forms in early trials but recombinant protein is a research chemical. WADA prohibited. No NDA or IND for peptide form.

Research Evidence

CJC-1295 (without DAC)

RCT · 3 key studies · most recent 2026

Follistatin 344

No citations on file

Research Citations

CJC-1295 (without DAC)

RCT1997 · Journal of Clinical Endocrinology and Metabolism

Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)…

RCT1997 · Journal of Clinical Endocrinology and Metabolism

Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune syst…

Review2026 · JBJS Rev

Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Imp…

Follistatin 344

No citations on file.

About CJC-1295 (without DAC)

CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH analog that binds and activates pituitary GHRH receptors to stimulate brief, pulsatile growth hormone release. Lacking the Drug Affinity Complex, it is not albumin-bound and clears within roughly half an hour, producing discrete GH pulses rather than the sustained elevation of the DAC form.

Research Areas

GH and IGF-1 elevationsustained GHRH receptor agonismbody composition supportrecovery enhancementGH axis restoration

About Follistatin 344

Binds and neutralizes myostatin (GDF-8) and activin; removes the natural brake on muscle growth allowing supraphysiological hypertrophy

Research Areas

myostatin and activin A neutralization — dual TGF-β inhibitionskeletal muscle hypertrophy in transgenic animal modelssatellite cell activation and muscle protein synthesis reliefgene therapy context: Becker MD phase 1/2a trial safety established

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

CJC-1295 (without DAC)

Warnings & Cautions

Active malignancy — caution (GH/IGF-1 is mitogenic)Pregnancy — cautionKnown hypersensitivityGlucose intolerance / insulin resistance

Class-based (investigational)

Suggested Monitoring

IGF-1Fasting glucoseHbA1cInsulin

Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.

Regulatory Notes

global — WADA

This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.

source

Follistatin 344

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Used Together?

CJC-1295 (without DAC)

Ipamorelin
Research suggests Ipamorelin and CJC-1295 may produce enhanced growth hormone release effects when combined. CJC-1295 provides sustained GHRH receptor stimulation while Ipamorelin provides pulsatile ghrelin receptor stimulation — complementary pathways studied in GH secretion research.
GLP-1 agonists
Research notes metabolic pathway overlap between growth hormone-releasing peptides and GLP-1 agonists. Both compound classes influence metabolic signaling; limited research has studied their combined effects. Consult your prescriber before combining.

Price (per mg)

CJC-1295 (without DAC)

$8.20/mg

$7.07 – $11.29 range

42 vendors

View price index →Find providers →

Follistatin 344

$102.67/mg

$90.00 – $139.00 range

12 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

CJC-1295 (without DAC)

454 listed

Browse directory →

Providers offering

Follistatin 344

15 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

Related Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). CJC-1295 (without DAC) vs Follistatin 344 — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/cjc-1295/follistatin-344

https://peptidebase.io/peptides/compare/cjc-1295/follistatin-344 Methodology License Download JSON Download CSV